Biotech | January 21, 2022
Palleon announces IND clearance for first-in-class cancer immunotherapy
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
The extended collaboration will provide services relating to small molecules for both Forbion and BGV portfolio companies active in the biopharmaceutical space
This is the company’s first partnership arrangement in China
It provides Covid-19 detection and Omicron surveillance in less than two hours
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
Dr Woler joins Sygnature Discovery after the company received significant investment from Five Arrows Principal Investments, the European corporate private equity arm of Rothschild & Co, in 2021
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
Narayanan to lead SeQuent through next phase of consolidation and growth
Market data indicates that more than twenty percent of the new chemical entities being developed use roller compaction technology in their development and commercialization
Subscribe To Our Newsletter & Stay Updated
